ALK and lung adenocarcinoma: To further address this issue, we collected data on 6 patients with lung adenocarcinomas who were Ventana IHC ALK(D5F3)-positive and FISH-negative from 3 hospitals in Beijing, and assessed these patients clinically following the administration of crizotinib therapy.